First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?

J Clin Oncol. 2018 Apr 10;36(11):1060-1061. doi: 10.1200/JCO.2017.77.4315. Epub 2018 Feb 12.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Androgen Antagonists
  • Humans
  • Male
  • Prostatic Neoplasms*
  • Standard of Care*
  • Survival Analysis

Substances

  • Androgen Antagonists